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Sheep as a Model of Human Pregnancy
Studies in sheep have made significant contributions to our 
understanding of normal and abnormal fetal development, 
and have enabled scientists and clinicians to answer questions 
about the etiology and treatment of poor maternal, placental, 
and fetal health (Morrison et  al., 2018). One fundamental 
advantage of utilizing sheep as an animal model of human 
pregnancy is the ability to surgically implant a diverse range 
of physiological monitoring systems into both maternal and 
fetal compartments. Implanting indwelling catheters into the 
maternal and fetal vasculature (Meschia et al., 1965) enables 
repetitive materno-fetal blood sampling free from any con-
founding effects of maternal, and therefore fetal anesthesia. 
In addition, surgical manipulation of the ovine fetus has pro-
vided key foundational knowledge for novel in utero treatment 
options for conditions such as spina bifida and diaphragmatic 
hernia. Incredibly rich information on fetal well-being can be 
captured from a highly dynamic in utero environment under 
a variety of experimental conditions that cannot be achieved 
from studies of a human fetus.
While pregnant ewes appear tolerant of  abdominal/intra-
uterine surgery to access the fetus, effective postoperative an-
algesia is required both from an animal welfare perspective 
and to reduce the potential confounding effects of  pain on the 
physiological variables under investigation. The effectiveness 
of  postoperative analgesic regimens largely focus on maternal 
recovery. Whether or not the fetus is sensate, and therefore 
capable of  experiencing pain as we understand it, is difficult 
to quantify and requires consideration of  the physical, emo-
tional, and cognitive aspects of  pain perception. The fetus 
itself  may be relatively less perceptive of  postsurgical pain 
than its mother due to the physiological suppression of  cen-
tral nervous system activity by allopregnalone, a metabolite 
of  progesterone, which maintains the fetus in sleeping behav-
ioral states (Hirst et al., 2014; Mellor et al., 2005). Although 
the fetus may respond to painful stimuli, these reactions ap-
pear to be mediated via brainstem and subcortical pathways, 
and do not involve consciousness or awareness of  pain (Mellor 
et al., 2005). Despite the importance of  effective analgesia fol-
lowing surgery to instrument the fetus, we have observed that 
the type of  drug, route of  administration, and dosing schedule 
are often not reported.
In this review, we summarize the most commonly reported 
analgesics in sheep fetal vascular catheterization surgery 
(Table 1), discuss potential fetal impacts of  each drug, and re-
port original research conducted in our laboratory comparing 
the behavioral response to surgery following administration of 
Implications
• As a model of human pregnancy, research studies in 
catheterized fetal sheep have made significant contribu-
tions to our understanding of both normal and abnor-
mal fetal development.
• Owing to the invasive nature of catheterization surgery, 
effective postoperative analgesia is required.
• Decisions regarding appropriate analgesia should 
consider effectiveness in reducing maternal pain and 
fetal well-being as well as potential impacts upon fetal 
physiological parameters under investigation.
• The reporting of analgesic regimes in all research 
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two commonly used analgesics. We also provide a discussion 
of  relevant considerations to be made when deciding upon 
an analgesic regimen for postsurgery analgesia. Importantly, 
we limit our discussion to systemic maternal administration, 
which potentially impacts the fetus as well as the mother. 
Although local or regional analgesia to maternal surgical 
wounds is also commonplace, it is beyond the scope of  this 
review.
Commonly Used Analgesics for Sheep Fetal 
Catheterization Surgery
Xylazine
Xylazine has been widely used in veterinary medicine and 
preclinical research studies to induce sedation or as an ad-
junct to injectable and inhalational anesthetics (Lemke, 2004). 
Xylazine is also effective in reducing experimentally induced 
acute, peripheral pain in sheep (Nolan et al., 1987; Grant et al., 
1996), and has been used for postoperative maternal analgesia 
following fetal catheterization surgery, including within our 
own laboratory (Soo et al., 2017; Darby et al., 2018). Xylazine 
is an α2-adrenergic receptor agonist (Schwartz and Clark, 
1998) for which a significant proportion of  the antinociceptive 
effects are mediated via heteroceptors located in the dorsal 
horn of  the spinal cord (Kyles et al., 1993). However, xylazine 
has a relatively short half-life of  22 min (Garcia-Villar et al., 
1981), and bolus intravenous administration to an adult sheep 
provides analgesia to mechanical and thermal stimuli for ap-
proximately 60 min (Nolan et al., 1987). There are also well-
documented side effects following the use of  α2-adrenergic 
receptor agonists in a range of  species, including hypoxemia, 
bradycardia, and hypotension (reviewed by Kästner, 2006). 
These effects occur at the higher doses required for sedation 
and anesthesia, and may not impact hemodynamic or car-
diovascular measures at the lower doses used for analgesia 
(Grant and Upton, 2001). Nevertheless, the potential adverse 
consequences combined with a lack of  sustained analgesic ef-
fects raise concerns about the appropriateness of  xylazine as a 
postoperative analgesic.
Buprenorphine
Buprenorphine is a potent analgesic commonly used to al-
leviate pain in research animals (Nolan et al., 1987), and has 
also been used as a maternal analgesic following fetal sheep 
catheter surgery (Loughran et al., 2017). As a partial µ-opioid 
agonist, buprenorphine hyperpolarizes centrally located 
neurons by opening K+ and closing Ca2+ channels, thus pro-
viding antinociceptive effects for thermal stimuli for up to three 
and a half  hours (Waterman et  al., 1991). However, the an-
algesic effect following mechanical noxious stimuli in sheep is 
variable (Waterman et al., 1991). Following a surgical insult in 
lambs, buprenorphine is effective in providing short-term anal-
gesia as measured by behavioral responses to pain, but is less 
effective in reducing physiological responses such as cortisol 
secretion (Paull et al., 2008). Systemic administration to sheep 
has marked side effects, including agitation, chewing move-
ments, bleating, rapid and frequent head movements, and re-
spiratory depression (Nolan et al., 1987), and as a scheduled 
drug, the use, storage and administration of buprenorphine is 
heavily controlled.
Table 1. Dosing regimen for analgesics commonly used systemically in studies utilizing maternal and fetal catheter 
surgery
Analgesic Dose
Route of maternal 
administration Dosing schedule
Mechanism of 
action Potential fetal impacts References






Untested Limesand and Hay 
(2003), Jonker et al. 
(2008), Loughran 
et al. (2017)
Carprofen 1.4 mg kg−1 Intramuscular Day of surgery and 
repeated daily as 





Untested, although possible 
impacts upon ductus 
arteriosus patency
Allison et al. (2016), 
Cleal et al. (2017), 
Shaw et al. (2018)
Flunixin meglumine 2.2 mg kg−1 Intramuscular Day of surgery and 
repeated daily as 





Untested, although possible 
impacts upon ductus 
arteriosus patency
(Owens et al. (2007), 
Chang et al. (2016), 
Benjamin et al. 
(2017)
Meloxicam 0.5 mg kg−1 Subcutaneous Day prior to surgery 
and repeated daily 





No impact upon fetal 
hemodynamics or COX 
expression in fetal tissues
Rac et al. (2006), Rac 
et al. (2007)




Increases myometrial activity, 
transiently suspends fetal 
breathing and decreases 
fetal heart rate and PaO2
Jansen et al. (1984), 
Darby et al. (2018), 
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Non-steroidal anti-inflammatory drugs (NSAIDs) are also 
routinely used for postoperative pain management in veter-
inary medicine (Lamont, 2008). NSAIDs inhibit both major 
isoforms of  the cyclooxygenase (COX) enzyme (i.e., COX-1 
and COX-2) and inhibit the processing of  arachidonic acid 
to prostaglandins, thromboxanes, and leukotrienes (Vane and 
Botting, 1998), although relative inhibition of  these isoforms 
varies between NSAIDs. The therapeutic effects largely re-
sult from their inhibition of  prostaglandin production via 
the inducible COX-2 at sites of  inflammation, whereas many 
of  the side effects, such as gastrointestinal (GI) ulceration 
and bleeding, are attributed to inhibition of  the constitutive 
COX-1 isoform (reviewed in Brune and Patrignani, 2015). 
Commonly used NSAIDs for maternal analgesia following 
fetal catheterization surgery include the relatively nonselective 
COX inhibitors carprofen (Allison et  al., 2016) and flunixin 
meglumine (Owens et  al., 2007). Similarly, the COX-2– 
selective NSAID meloxicam has demonstrated efficacy in redu-
cing pain and inflammation following experimentally induced 
lameness (Colditz et al., 2019) and provides partial analgesia 
to lambs following ring castration (Paull et al., 2012). Due to 
its preferential inhibition of  COX-2 over COX-1 (Engelhardt 
et  al., 1996), meloxicam has a superior tolerance profile 
for upper GI tract effects in humans (Hawkey et  al., 1998). 
Furthermore, unlike xylazine or buprenorphine, meloxicam 
does not cause respiratory suppression and can therefore be 
administered prior to surgery, thus ensuring plasma levels are 
at their highest at the time of  the insult. With a half-life of 
14 hr in nonpregnant sheep, the analgesic effects of  meloxicam 
are sustained (Stock et al., 2013). However, NSAIDs are used 
with caution perioperatively in humans due to potential for 
renal dysfunction (Bell et al., 2018), although we are not aware 
of  similar concerns in sheep.
Paracetamol administration has been given postoperatively 
to sheep recovering from fetal catheterization surgery 
(Malhotra et al., 2018). Although not an NSAID, paracetamol 
does suppress prostaglandin production by inhibition of COX. 
The analgesic properties of paracetamol, however, likely arise 
at multiple levels in the pain stimulus conduction pathway, 
including at tissue receptors, spinal cord, thalamus, and the 
cerebral cortex in which pain sensations are evoked (Jóźwiak-
Bebenista and Nowak, 2014).
Additional Considerations When Administering 
Analgesics During Pregnancy
Analgesic administration to pregnant ewes may have sig-
nificant direct and indirect consequences for the fetus and may 
threaten the integrity and/or reproducibility of research out-
comes. It is, therefore, important to consider both maternal and 
fetal effects of analgesia when deciding upon an analgesic re-
gime (Figure 1).
Bolus xylazine administration to pregnant ewes increases 
myometrial activity, suspends fetal breathing, and decreases 
fetal heart rate and the partial pressure of oxygen (PaO2) (Jansen 
et al., 1984), although these effects are relatively transient and 
are unlikely to have long-term impacts upon the fetus. We are 
unaware of any studies examining the impact of maternal 
buprenorphine administration upon fetal lamb physiology; 
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however, ex vivo studies of human term placenta suggest that 
there is low transplacental transfer of buprenorphine to the 
fetus (Nanovskaya et al., 2002).
Despite their widespread use and well-documented tol-
erability in nonpregnant animals, there are major concerns 
around the use of  NSAIDs during pregnancy. Patency of  the 
fetal ductus arteriosus (key to normal fetal cardiorespiratory 
status) is maintained by circulating prostaglandins derived 
from the placenta and by the low oxygen tension normally 
present in the fetus (Coceani and Olley, 1988). In humans, it 
is recommended that NSAIDs are not used in the third tri-
mester of  pregnancy (Walker and Misan, 1997) due to inhib-
ition of  prostaglandin synthesis increasing the risk of  fetal, 
rather than postnatal, closure of  the ductus arteriosus (Koren 
et al., 2006). Whether postoperative NSAID administration 
to sheep, in the doses required for analgesia, has detrimental 
impacts upon ductus arteriosus patency is unknown. Both 
COX-1 and COX-2 are expressed in the fetal sheep ductus 
arteriosus (Clyman et  al., 1999), and in vitro inhibition of 
either isoform can cause contraction (Clyman et  al., 1999). 
Furthermore, infusion of  selective COX-2 inhibitors dir-
ectly into the fetal vasculature (at doses much greater than 
experienced following maternal analgesic administration) in-
duces contraction of  the ductus arteriosus (Takahashi et al., 
2000). However, in a sheep model of  preterm labor, maternal 
meloxicam administration does not affect fetal acid–base 
status, plasma osmolality, arterial pressure, heart rate, or re-
gional blood flow to the fetal kidney, intestine, adrenal glands, 
or cotyledon (Rac et al., 2006). Maternal meloxicam admin-
istration also does not affect COX expression in fetal kidney, 
small intestines, lung, liver, or heart (Rac et al., 2007). These 
results clearly demonstrate that a consideration of  fetal im-
pacts is warranted when developing analgesic regimes for pre-
clinical research.
Recent Experience
Decisions about postoperative analgesic regimen must con-
sider effectiveness, duration of pain relief, potential side effects, 
and fetal impacts. Owing to concerns around sustained effective-
ness, we transitioned from the use of xylazine analgesia to a re-
gime of subcutaneous administration of meloxicam on the day 
prior to and following surgery, for all maternal/fetal indwelling 
catheter procedures conducted in our laboratory from 2017 on-
wards. Here we retrospectively compare the behavioral impact 
of meloxicam with xylazine, as assessed by prospective docu-
mentation of postoperative clinical condition, including feed 
intake. Studies using xylazine analgesia (2013–2016) and those 
using meloxicam analgesia (2017–2018) were all conducted at 
the South Australian Health and Medical Research Institute 
(SAHMRI) Preclinical Imaging Research Facility (PIRL), in 
accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes (National Health 
and Medical Research Council 2013), and with approval from 
appropriate local Animal Ethics Committees.
Merino ewes between 105 and 125  days of gestation 
(term = 150 ± 3 days of gestation) were housed individually 
in a 12:12 (light:dark) hr photoperiod with ad libitum access 
to water. Animals were daily fed 1 kg lucerne chaff (85% dry 
matter, metabolizable energy content  =  8.3 MJ kg−1) supple-
mented with pellets containing straw, cereal, hay, clover, barley, 
oats, lupins, almond shells, oat husks, and limestone (singletons 
300 g, twins 500 g; 89% dry matter, metabolizable energy con-
tent = 11.6 MJ kg−1). Anesthesia was induced with diazepam 
(0.3  mg kg−1, intravenous) followed by ketamine (7  mg kg−1, 
intravenous), then maintained with 1.5% to 2.5% isoflurane in 
oxygen. Vascular catheters were implanted into the maternal 
jugular vein, fetal femoral artery and vein as well as the am-
niotic cavity as described previously (Danielson et al., 2005). 
Figure 2. Determination of total clinical score as developed with the SAHMRI Animal Ethics Committee. Ewes are assessed daily by a trained animal techni-
cian and scored on a scale of 0 to 3 for each of the indicators as described to generate a total clinical score. Scores >2 require escalation of monitoring and care, 
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Fetal catheters were exteriorized through a small incision in 
the ewe’s flank. At surgery, antibiotics were administered intra-
muscularly to the ewe (3.5 mL of 150 mg mL−1 procaine peni-
cillin, 112.5 mg mL−1 benzathine penicillin, plus 2 mL of 250 g 
mL−1 dihydrostreptomycin) and fetus (1 mL of 150 mg mL−1 
procaine penicillin, 112.5 mg mL−1 benzathine penicillin, plus 
1 mL of 250 g mL−1 dihydrostreptomycin). Antibiotics were ad-
ministered intramuscularly to each ewe for 3 days after surgery 
and intra-amniotically (5 mL of 100 mg mL−1 ampicillin) for 4 
days after surgery.
Analgesia and clinical monitoring
Ewes were administered xylazine (20 µg kg−1, intramuscular, 
n = 50) upon recovery from anesthesia, or meloxicam (0.5 mg 
kg−1, subcutaneous, n = 56) at 1600 hr on both the day prior to 
and day of surgery. Daily food consumption was determined 
by weighing daily food offered and residual feed. Routine clin-
ical records were collected for 3 d prior and up to 6 d following 
surgery by trained animal technicians who were not members 
of the research group. Ewes were assessed each morning and 
scored on a scale of 0 to 3 for appetite, drinking, defecation, 
urination, alertness, and surgical site, where 0 is normal and 
3 is severely affected (Figure 2). A total clinical score was cal-
culated as the sum of all scores for each animal and used to 
determine the appropriate level of monitoring and care as fol-
lows: score of ≥2, twice daily monitoring; ≥4, report to prin-
ciple investigator and animal welfare officer; ≥6, seek veterinary 
assessment and treat as advised; and ≥10, humane euthanasia 
followed by post mortem. Total clinical scores and food con-
sumption were analyzed by a linear mixed model to assess 
effects of treatment (xylazine and meloxicam) and time (day 
postsurgery) as a repeated measure, with Bonferroni correction 
for post hoc comparisons at each postsurgical day (IBM SPSS 
Statistics for Windows, Version 25, Armonk, NY).
Results
The effect of surgery on total clinical scores in singleton- 
and twin-bearing ewes depended on the type of analgesia used 
(surgery vs. analgesic interaction: singleton P  =  0.003, twin 
P  <  0.001). In singleton-bearing ewes administered xylazine, 
surgery increased total score at day 1 (1.5 ± 0.4, P = 0.001), 
day 2 (1.4 ± 0.4, P = 0.001), and day 3 (1.2 ± 0.4, P = 0.036) 
postsurgery (Figure 3A). In twin-bearing ewes adminis-
tered xylazine, surgery increased total score at day 1 (1.7  ± 
0.4, P = 0.001) and day 2 (1.8 ± 0.4, P = 0.001) postsurgery 
(Figure  3B). However, surgery did not alter total clinical 
scores in either singleton- or twin-bearing ewes administered 
meloxicam (singleton P = 0.616, twin P = 0.095).
Figure 3. Change in total clinical record score (A and B) and food consumption (C and D) compared with presurgical measures following fetal indwelling cath-
eter surgery in ewes administered xylazine (20 µg kg−1; given as a single postoperative dose; red circles; singleton, n = 36; twin, n = 14) or meloxicam (0.5 mg 
kg−1; given preoperatively 16 to 24 hr prior and at surgery; blue squares; singleton, n = 36; twin, n = 20). Significant differences from baseline are shown by * in 






/af/article-abstract/9/3/60/5522876 by Acquisition D
ept.(Journals) user on 24 O
ctober 2019
65July 2019, Vol. 9, No. 3
Similarly, the effect of  surgery on food consumption in 
singleton- and twin-bearing ewes depended on the type of  an-
algesia (surgery vs. analgesic interaction: singleton P = 0.04, 
twin P  <  0.001). In singleton-bearing ewes administered 
xylazine, surgery reduced food consumption at day 1 (−387 ± 
91 g, P = 0.001), day 2 (−403 ± 93 g, P < 0.001), and day 3 
(−293 ± 91 g, P = 0.034) postsurgery (Figure 3C). In twin-
bearing ewes administered xylazine, surgery reduced food 
consumption at day 2 (−536 ± 165 g, P = 0.034) postsurgery 
(Figure 3D). In comparison, postsurgery food consump-
tion in ewes administered meloxicam was significantly re-
duced only at day 4 (−276  ± 77  g, P  =  0.008) and only in 
singleton-bearing ewes.
These results demonstrate that with our previous analgesic 
regimen of postsurgical xylazine administration, ewes experi-
enced an increase in total clinical scores and reduced appetite 
for up to 3 d postsurgery. In contrast, these clinical indicators 
were largely unchanged in ewes administered meloxicam. While 
this suggests meloxicam provides superior analgesic protection 
to ewes following fetal indwelling catheter surgery, an analysis 
of quantifiable parameters that directly assess severity of pain, 
for example, the Sheep Grimace Scale (Häger et al., 2017), and 
plasma cortisol as a marker of the physiological stress response 
are required to confirm this.
Into the Future
In this review, we have discussed the effectiveness and 
possible complications of analgesics commonly used in sheep 
fetal catheterization studies. The primary consideration when 
choosing an analgesic regimen should be effectiveness. Largely 
this has involved assessment of maternal behavioral and 
physiological responses to painful stimuli, and the ability of 
analgesia to mitigate the response. Fetal perceptions of cath-
eterization should also be considered, and whether systemic 
maternal administration is likely to have any benefit for the 
fetus. However, unlike the ewe, it is not possible to accurately 
or directly assess the impact of analgesia on the fetus. Without 
the surgically implanted monitoring lines, assessment of fetal 
condition relies on indirect measures (e.g., ultrasound) taken 
at a point in time that may not be representative or relevant. 
Nevertheless, considerations such as route of administration, 
transport across the placenta, and placenta drug metabolism 
may influence decisions.
Specific analgesic drugs or drug classes may be more or less 
appropriate depending on the main outcomes of interest. Fetal 
catheterization studies cannot be ethically or scientifically jus-
tified if  the analgesic regimen compromises scientific outcomes. 
Furthermore, the choice of an appropriate analgesic regimen 
for specific studies will need to consider issues such as com-
parability with previous work and the need to maintain con-
sistency throughout an experimental series, to avoid the ethical 
impact of additional animals needed to repeat previous work. 
Ideally, factors influencing analgesic choice will be considered 
and changes implemented at the start of a new series of studies. 
In addition, restrictions on access to, or the personnel allowed 
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to administer, some classes of licensed drugs, may restrict avail-
able options.
Finally, critical to any studies involving maternal and fetal 
surgery is the need to report the analgesic regimen including 
dose, route of administration and regimen, as prescribed by 
the ARRIVE guidelines (Kilkenny et al., 2010) and required by 
some journals (Grundy, 2015).
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